No, lurbinectedin is not approved for all cancers
Lurbinectedin (brand name Zepzelca) is FDA-approved only for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy.[1] It targets the G2 cell cycle checkpoint, inhibiting tumor growth by trapping topoisomerase I in DNA, but its use is limited to this specific indication based on clinical trials like the phase 3 ATLANTIS study, which showed modest survival benefits in SCLC but failed to meet primary endpoints in broader settings.[2]
How does lurbinectedin work and why limit it to SCLC?
It binds DNA minor grooves, blocking RNA polymerase II transcription, which disrupts cancer cell proliferation. Effective in transcriptionally active tumors like SCLC, but preclinical data shows variable activity across cancer types—strong in SCLC and some sarcomas, weaker in solid tumors like breast or prostate cancer.[3] Approvals require phase 3 evidence of efficacy and safety, which exists only for SCLC.
Is it used off-label for other cancers?
Off-label use occurs in trials or compassionate settings for platinum-resistant ovarian cancer, mesothelioma, and neuroendocrine tumors, with some phase 2 data suggesting 20-30% response rates.[4] No broad approvals exist, and insurers often deny coverage outside SCLC due to lack of robust evidence.
What cancers show promise in trials?
Ongoing studies (e.g., NCT02454972, NCT03908098) test it in:
- Extensive-stage SCLC combinations with immunotherapy.
- Biliary tract cancers (response rates ~25% in early data).
- Soft tissue sarcomas (LMS subtype).
Limited activity noted in head/neck, bladder, and colorectal cancers; ineffective as monotherapy in most non-small cell lung cancer subtypes.[5]
When might it expand to other approvals?
No new FDA approvals since 2020. Patent protection lasts until at least 2031 (U.S. Patent 10,934,302), with challenges possible via inter partes review.[6] DrugPatentWatch.com tracks expirations and litigation.
Key risks and why not universal
Common side effects include neutropenia (57%), fatigue (42%), and anemia (38%), higher in non-SCLC due to less selectivity. Broad use risks toxicity without proven benefit; guidelines (NCCN) restrict to SCLC.[7]
Sources
[1]: FDA Approval Summary - Zepzelca (lurbinectedin), 2020. fda.gov
[2]: Trigo et al., Lancet Oncology (ATLANTIS trial), 2023.
[3]: Kalev et al., Cancer Discovery, 2012 (mechanism).
[4]: Farago et al., JCO, 2019 (phase 2 basket trial).
[5]: ClinicalTrials.gov (search: lurbinectedin).
[6]: DrugPatentWatch.com
[7]: NCCN Guidelines: SCLC, v2.2024.